Grant ID RP140468
Awarded On August 20, 2014
Title Targeting of Chronic Lymphocytic Leukemia by Designer T Cells
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization The University of Texas M.D. Anderson Cancer Center
Principal Investigator/Program Director Partow Kebriaei
Cancer Sites Leukemia
Contracted Amount $900,000
Lay Summary

Immunotherapy was named as Breakthrough of the Year for 2013. One reason for this accolade is the spectacular clinical responses achieved after infusion of tumor-specific T cells in some patients with leukemias and lymphomas arising from cancerous B cells. The T cells were rendered specific for the molecule CD19, which is expressed on most malignant B cells. This was achieved through the insertion of a chimeric antigen receptor (CAR) that signals genetically modified T cells to kill upon docking with CD19. Infusions of CD19-specific CAR+ T cells resulted in eradication of tumor cells that had otherwise been refractory to treatment with conventional therapies. Our immunotherapy program at MD ...

Read More